抑制颌骨骨髓间充质干细胞铜死亡经FoxO通路减轻根尖周炎骨丢失
根尖周炎(AP)以根尖周炎症和牙槽骨破坏为特征,铜死亡是铜调控的细胞死亡形式。该研究通过人体标本、单细胞RNA测序、大鼠AP模型和体外实验,发现AP中铜浓度升高且铜死亡主要发生于颌骨骨髓间充质干细胞(JBMMSCs),铜螯合剂TTM可减轻大鼠牙槽骨丢失并恢复成骨能力,机制涉及铜死亡/FoxO/β-catenin通路。
要点
- AP患者和大鼠根尖周组织中铜浓度显著升高,铜死亡主要发生在JBMMSCs。
- TTM通过减少JBMMSCs铜死亡减轻大鼠牙槽骨丢失并恢复成骨能力。
- 铜死亡经FoxO/β-catenin轴损害JBMMSCs成骨潜能,抑制FoxO可挽救。
核心结论
- 铜死亡通过损害JBMMSCs成骨潜能驱动AP牙槽骨丢失,靶向铜死亡(如TTM)经铜死亡/FoxO/β-catenin通路减轻骨吸收。
研究设计与样本
- 收集健康者和AP患者根尖周标本评估铜含量及铜死亡相关蛋白表达。
- 重新分析单细胞RNA测序数据集GSE171213、GSE181688和GSE197680以识别发生铜死亡的细胞类型。
- 构建AP大鼠模型并用铜螯合剂四硫钼酸盐(TTM)处理,通过micro-CT、H&E染色、铜离子染色和免疫组化评估牙槽骨丢失。
- 体外用LPS或铜死亡诱导剂Elesclomol-Cu刺激JBMMSCs模拟AP微环境,并用JY-2(FoxO抑制剂)处理铜死亡JBMMSCs。
- 采用LC-MS/MS蛋白质组学探究TTM减轻骨丢失的机制。
主要发现
- 与健康组织相比,人和大鼠AP组织中铜浓度显著升高。
- 单细胞RNA测序分析显示铜死亡主要发生于JBMMSCs。
- 大鼠模型中,TTM给药通过减少JBMMSCs铜死亡显著减轻牙槽骨丢失。
- LPS或Elesclomol-Cu刺激的JBMMSCs表现出铜死亡特征和成骨功能受损,TTM处理可减少铜死亡并恢复成骨能力。
- 铜死亡导致JBMMSCs中FoxOs去磷酸化,TTM在体内外逆转这些变化;JY-2抑制FoxO信号破坏FoxO3/β-catenin相互作用、增强β-catenin表达并挽救铜死亡诱导的成骨功能障碍。
临床怎么用
- 铜死亡及其FoxO/β-catenin通路可能作为AP骨丢失的干预靶点。
- 铜螯合剂TTM在动物实验中显示减轻AP牙槽骨丢失的潜力,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Apical periodontitis (AP) is an infectious disorder characterized by periapical inflammation and alveolar bone destruction. Recent evidence suggests that cuproptosis, a distinctive form of copper-regulated cell death, has been implicated in the regulation of bone loss. This study aimed to investigate the involvement of cuproptosis and its mechanism in modulating bone loss in AP. METHODOLOGY: Periapical specimens from healthy subjects or AP patients were collected to evaluate copper content and the expression level of cuproptosis-associated proteins. Single-cell RNA sequencing (scRNA-seq) datasets (GSE171213, GSE181688, and GSE197680) were re-analysed to identify the specific cell types undergoing cuproptosis. An AP rat model was constructed and treated with the copper chelator tetrathiomolybdate (TTM). Alveolar bone loss was assessed using micro-CT, H&E staining, copper ion staining, and immunohistochemistry. In vitro, jaw bone marrow mesenchymal stem cells (JBMMSCs) were stimulated with lipopolysaccharide (LPS) or cuproptosis inducer (Elesclomol-Cu) to mimic the AP microenvironment. The effects of TTM on osteogenic differentiation were examined via qRT-PCR, Western blotting, ALP staining, and ARS staining. LC-MS/MS proteomics was utilized to explore the mechanism by which TTM attenuates bone loss. Moreover, cuproptotic JBMMSCs were treated with JY-2 (FoxO inhibitor) to determine whether cuproptosis aggravates osteogenic dysfunction via the FoxO/β-catenin axis. RESULTS: Copper concentrations were significantly elevated in human and rat AP tissues compared with healthy tissues. Analysis of scRNA-seq data revealed that cuproptosis predominantly occurred in JBMMSCs. In the rat model, TTM administration significantly alleviated alveolar bone loss by reducing cuproptosis in JBMMSCs. Furthermore, JBMMSCs stimulated with LPS or Elesclomol-Cu exhibited characteristics of cuproptosis and impaired osteogenic function. TTM treatment markedly reduced cuproptosis and restored osteogenic capacity. Mechanistically, cuproptosis in JBMMSCs led to the dephosphorylation of FoxOs. Conversely, TTM reversed these changes both in vivo and in vitro. Furthermore, inhibition of FoxO signalling with JY-2 disrupted FoxO3/β-catenin interaction, enhanced β-catenin expression and rescued the osteogenic dysfunction induced by cuproptosis. CONCLUSIONS: Cuproptosis acts as a novel driver of alveolar bone loss in AP by impairing the osteogenic potential of JBMMSCs. TTM targeting cuproptosis represents a promising strategy to attenuate bone resorption in AP by the cuproptosis/FoxO/β-catenin pathway.
引用
- Zhang K, Ma Z, Wen B, et al. Inhibition of Jaw Bone Marrow Mesenchymal Stem Cell Cuproptosis Attenuates Bone Loss in Apical Periodontitis via Suppressing the FoxO Signalling Pathway. Int Endod J. 2026. PMID: 42746789. doi:10.1111/iej.70266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。